Physician profile

Christopher S Choi

Internal Medicine · Las Vegas, NV

NPI 1730117656

$6,679.40

in general payments reported to CMS, 2019-2025

45 companies · $554 in 2025

The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,719.43
Education$32.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,372.94 2020-2025 Repatha, Repatha, Otezla
Biohaven Pharmaceuticals, INC. $1,243.81 2021
Astrazeneca Pharmaceuticals Lp $647.43 2019-2025 Farxiga, Airsupra
Abbvie INC. $337.69 2022-2025 Vraylar, Qulipta
Novo Nordisk INC $302.84 2019-2024 Ozempic, Rybelsus
Novartis Pharmaceuticals Corporation $252.26 2023-2025
Eisai INC. $203.37 2020-2022
Abbott Laboratories $183.94 2022-2024 Freestyle Libre 2, Freestyle Libre 3
Teleflex LLC $179.39 2024 Urolift
Lilly USA, LLC $167.33 2023-2024 Mounjaro, Jardiance, Emgality
Boehringer Ingelheim Pharmaceuticals, INC. $165.49 2019-2025 Jardiance
Radius Health, INC. $149.12 2023-2025 Tymlos
Corcept Therapeutics $135.67 2022-2023 Korlym
Avanir Pharmaceuticals, INC. $129.73 2019-2021
Ucb, INC. $123.50 2019-2021
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Merz North America, INC. $120.78 2025
Pfizer INC. $110.27 2019-2025
Merck Sharp & Dohme LLC $102.87 2020-2021
Vanda Pharmaceuticals INC. $93.00 2021-2023 Fanapt, Hetlioz
Genentech USA, INC. $48.17 2020-2021
Astellas Pharma US INC $38.39 2024-2025 Veozah
Currax Pharmaceuticals LLC $34.27 2021-2022
Exact Sciences Corporation $33.96 2023 Cologuard Collection Kit
Lundbeck LLC $33.41 2024 Vyepti
Qol Medical, LLC $32.64 2019-2021
Phathom Pharmaceuticals, INC. $32.40 2024-2025 Voquezna
Itamar Medical INC $31.40 2024 Watchpatone
Amneal Pharmaceuticals LLC $31.39 2020-2021
Boston Scientific Corporation $31.33 2020
Bayer Healthcare Pharmaceuticals INC. $29.69 2023
Lucid Diagnostics INC. $29.60 2025
Antares Pharma, INC. $28.50 2025 Xyosted
Alfasigma USA, INC. $24.32 2021
Otsuka America Pharmaceutical, INC. $23.05 2023 Rexulti
Esperion Therapeutics, INC. $19.97 2021
Neos Therapeutics, Lp $18.86 2019
Vyera Pharmaceuticals, LLC $18.28 2019
Arbor Pharmaceuticals, INC. $17.09 2020
Acadia Pharmaceuticals INC $16.90 2024 Daybue
Kowa Pharmaceuticals America, INC. $15.68 2024 Livalo
Tolmar, INC. $15.05 2025 Jatenzo
Nestle Healthcare Nutrition INC. $14.94 2021
Tactile Systems Technology INC $14.69 2019
Bardy Diagnostics, INC. $12.06 2021
Cmp Pharma, INC. $11.93 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher S Choi

$6,679.40

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/168708/christopher-s-choi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.